renovarobio.com (RENB): Debts to Book Capitalization

Graphic logo of Renovaro (RENB)

Renovaro Inc. focuses on expanding AI diagnostics and immunotherapy to capture the oncology market. Demand for such services remains independent of economic conditions, while the absence of manufacturing plants minimizes the environmental footprint. This debt-to-equity chart confirms financial stability, with the 0.08 value aligning with current metrics, signaling low leverage and a conservative approach to investments.

Renovaro Biosciences (RENB) - Debts to Book Value from 02/21/2024 to 10/01/2025
Core merchandise of renovarobio.com

The lack of profitability in AI diagnostics integration and high laboratory costs at Renovaro Inc. (RENB) make credit load control critical. This indicator compares total liabilities to balance sheet capital, measuring the company's degree of financial leverage. By analyzing the change in the ratio of total debt to balance sheet capitalization on GURU.Markets, an investor assesses the default risk relative to equity. An increase in this metric signals overheating of borrowings, while a steady decline confirms the long-term stability of assets.

Who Renovaro Inc. competes with

ONC - Debt to Book Capitalization Ratio|Debt to Book Value Ratio halozyme.com HALO|RVMD: Debts to Book Capitalization|AAPG - Debt to Book Value|Debts to Book Capitalization CGON|URGN (UroGen Pharma Corp) - Debts to Book Value|BCAX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio personalis.com (PSNL)|Erasca (ERAS) - Debt to Book Value|Debt to Net Assets Ratio Delcath Systems Inc (DCTH)|YmAbs - Debts to Book Capitalization|AURA - Debt to Book Value|Candel - Debt to Book Value|ARAY: Debts to Book Capitalization|Debt to Book Capitalization Ratio sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Debt to Net Assets Ratio|Debts to Book Capitalization CTOR (Citius Oncology, Inc)|Debts to Book Value HURA|Protara Therapeutics (TARA) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio fatetherapeutics.com (FATE)|WHWK: Debts to Book Capitalization|TScan Therapeutics Inc - Debts to Book Value|Champions Oncology Corp (CSBR) - Debt to Book Capitalization Ratio|XBIT: Debt to Book Value Ratio|Debt to Book Capitalization Ratio CVM|Debts to Book Value ostherapies.com|Debt to Book Value Radiopharm Theranostics Limited|Debt to Book Capitalization Ratio Artiva|Debts to Book Capitalization ANL|Debts to Book Capitalization VERU (Veru Corporation)|Debt to Book Capitalization Ratio Tempest Therapeutics|Xilio Therapeutics Inc - Debt to Net Assets Ratio|MURA (Mural Bio) - Debt to Book Capitalization Ratio|Kairos Pharma Ltd (KAPA) - Debts to Book Value|Debt to Book Value onkuretherapeutics.com OKUR|CytoMed Therapeutics Limited (GDTC) - Debt to Net Assets Ratio|CRIS: Debts to Book Capitalization|Debts to Net Assets APLM|Debt to Book Capitalization Ratio Tharimmune THAR|Debt to Book Value Ratio advanbiomed.com (ADVB)|Genprex, Inc - Debts to Book Capitalization|CLDI - Debt to Book Value|Debt to Book Value SBFM (Sunshine Biopharma, Inc.)|XBIO: Debts to Net Assets|Debt to Book Capitalization Ratio Salarius Pharmaceuticals, Inc. SLRX|Purple Biotech Ltd (PPBT) - Debt to Net Assets Ratio|Debts to Book Capitalization AONC (American Oncology Network Inc)|Debts to Book Value BGNE|Debt to Book Capitalization Ratio Checkpoint Therapeutics CKPT|Debt to Book Value Ratio elevationoncology.com (ELEV)|Debts to Book Capitalization iCAD ICAD|Debt to Book Capitalization Ratio Ikena Oncology Inc. IKNA|NTBL: Debts to Book Capitalization|VIRX - Debt to Book Value|MOR: Debts to Book Capitalization|NAYA (nayabiosciences.com) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Ascentage Pharma (AAPGV)